Remedium Lifecare Ltd. (BSE: 539561), a company engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, has announced that its board will meet on May 10, 2024, to consider and approve the Audited Financial Results for the quarter and Financial Year ended 31 st March 2024, and to consider recommendation and approval of the issue of Bonus Shares to the existing Equity Shareholders of the Company.
Remedium Lifecare Ltd., a company engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, has bolstered its performance and
presence within the pharmaceutical and healthcare domains by trading amino isophthalic acid, tellurium oxide, grignard reagent, iodine, selenium metal powder, trimethyl sulfoxonium iodide (TMSI). As a leading contract trader and brand owner of advanced intermediates and APIs, Remedium has shifted its paradigm into the trading of intermediates and APIs.
Reflecting the ethos of its chairman, who believes in “working hard in silence and letting
success make the noise”, Remedium is dedicated to upholding uncompromising quality
standards. Remedium has consistently raised the industry’s benchmarks through its commitment to developing intermediates (KSMs & CRMs) and APIs that deliver unique value to patients and societies worldwide. Adapting swiftly to evolving demands, the company has
emerged as one of the fastest-growing organizations in the global pharmaceutical industry.
“Quality is an ongoing process of building and sustaining relationships,” is the firm belief at
Remedium. Its unwavering commitment to quality products is backed by a highly qualified team of professionals, a cutting-edge infrastructure, and deep industry knowledge. Remedium strives to create mutually beneficial partnerships, adhering to high-quality standards as a matter of habit rather than chance.
Remedium is passionate about excellence and strives to deliver products with 0% defects, earning trust as a reliable source for quality pharmaceutical and healthcare products. It is
committed to a rigorous product development process that involves constant modernization
and adherence to international standards, since it has one of the largest portfolios of intermediates and active pharmaceutical ingredients (APIs), responsible for the therapeutic
effects of various medicines.
Besides contributing to society’s well-being and health, the company’s vision is to become a well-known pharmaceutical multinational corporation in the pharmaceutical and healthcare
industries. Remedium remains steadfast in its commitment to excellence, innovation, and societal well-being, driving positive change in the healthcare landscape.